CEL-SCI Corporation is heading into its May 13 earnings with short sellers rebuilding aggressively — and the stock at its weakest price in months.
Short interest has nearly doubled in a week. SI % FF climbed from roughly 5% at the start of April to a peak of 10.2% on April 27, settling back slightly to 9.6% on April 28. That 92% week-on-week jump is the sharpest build in the 30-day window. The ORTEX short score confirms the pressure: it hit 80.9 on April 27 before easing to 79.4, placing CVM in the top tier of the universe for short-side conviction. The score has risen nearly 20 points over just two weeks — from 60.6 on April 20 to 80.9 by April 27. That is a rapid re-rating.
The borrow market tells a supporting story. Cost to borrow has risen 46% over the week to 5.5%, a multi-month high, having barely exceeded 3.5% through most of April. Availability has tightened in parallel — the borrow pool is less than half utilised at 54% of available shares now lent out, down from a 52-week peak of 95%, but the directional move this month has been distinctly tighter. The combination of a rising short count, climbing borrow costs, and an accelerating short score points to deliberate conviction-building rather than passive drift.
The stock itself is down 20% on the week and 5% over the past month, now trading at $3.04 — near the bottom of its three-month range. That price action matters for context: the short build is not just a response to a squeeze unwinding; it appears to be running concurrently with the selloff. Close peers and also fell sharply — PRQR down 15% on the week, HOWL off 18% — suggesting broad weakness across small-cap clinical-stage biotechs, rather than a CVM-specific catalyst alone.
The one analyst covering the stock has a $25 price target on record, but this data is from early March and should be treated with caution given the stock's current level at $3.04. The gap is too wide to reconcile confidently without a more recent update, so that figure is not meaningful context here. The company's EV stands near $33 million, reflecting its micro-cap status. On insider activity, CEO Geert Kersten bought $200,000 worth of shares in January at $5.26 — a level the stock has since fallen well below. That purchase, combined with Kersten appearing in the top-holders list at 1.5% of shares, puts him on the wrong side of the trade for now.
The recent earnings record adds to the sense of binary risk around the May 13 print. The last four events produced moves of -8%, +6%, -7%, and +11% on day one — there is no consistent directional pattern, but the average absolute move has been meaningful. The five-day reactions tell a bleaker story: three of the four episodes ended with the stock lower a week out, including a -16% five-day move after the January 7 event. With short interest at its highest level in the trailing 30 days and borrowing costs accelerating, the setup into the next print is more charged than it was even a fortnight ago — and how the lending market responds in the days after May 13 will be the clearest signal of whether short sellers treat that print as a resolution or a starting point.
See the live data behind this article on ORTEX.
Open CVM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
